Emcure Pharmaceuticals has confirmed that its promoters and persons acting in concert did not create any fresh encumbrance on their equity shareholdings during the financial year ended March 31, 2026. The disclosure, made to the National Stock Exchange of India Limited and BSE Limited, aims to comply with regulatory transparency requirements regarding share pledges by key shareholders.

The declaration, signed by Promoters Satish Mehta, Sunil Mehta, Samit Mehta, and Namita Thapar, confirms that no new pledges were made directly or indirectly by the promoter group during FY26. However, the filing notes that an existing encumbrance involving Mrs. Smita Paresh Shah, a member of the promoter group, remains active. She had pledged 60,000 equity shares during the financial year 2024-25, and these shares continue to remain pledged as of March 31, 2026.

Promoter Group Details

The filing identified the individuals and entities classified as promoters and persons acting in concert. The list includes four individual promoters and 37 entities categorized under the promoter group, comprising family members, private limited companies, and trusts.

The list of entities includes firms such as Uth Beverage Factory Private Limited, Thapar Ventures Private Limited, and Avet Lifesciences Private Limited. Trusts such as Indus Trust, Unity Trust, and Himalayan Trust are also included within the promoter group definition.

Regulatory Compliance

The disclosure was submitted pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to declare any encumbrance on shares held by them or persons acting in concert. The company has requested the exchanges to place the information on their records.

Emcure Pharmaceuticals has received a reaffirmed Buy rating from global brokerage Jefferies, which has simultaneously raised its target price to ₹2,100. The revised target reflects growing confidence in the company's near-to-medium-term growth trajectory, anchored by a combination of operational improvements, strategic global expansion, and a disciplined focus on research and development.

Key Highlights of the Jefferies Rating

The brokerage's updated assessment covers several dimensions of Emcure Pharmaceuticals' business outlook. The following table summarises the key parameters cited by Jefferies:

Growth Drivers Identified

Jefferies has outlined several factors underpinning its positive stance on Emcure Pharmaceuticals. The brokerage expects revenue growth in the low-to-mid teens range for FY27, reflecting momentum across the company's business segments. On the profitability front, a 75–100bps expansion in EBITDA margins is anticipated, attributed to higher field-force productivity and contributions from global product launches.

The brokerage also highlights Emcure Pharmaceuticals' R&D-led growth focus as a key long-term differentiator. This strategic emphasis on research and development is seen as a driver of sustained earnings improvement, with Jefferies projecting a 20% EPS CAGR over the FY26–29E period.

Valuation Perspective

In addition to the operational and growth factors, Jefferies has cited attractive valuations as a supporting rationale for its Buy recommendation. The combination of an improving earnings profile and what the brokerage considers favourable valuations forms the basis for the raised target price of ₹2,100.

The maintained Buy rating and upward revision in target price collectively signal Jefferies' constructive outlook on Emcure Pharmaceuticals' ability to deliver consistent financial performance over the coming years, driven by field-force efficiency, global market expansion, and a robust R&D pipeline.